BIOXYTRAN, INC 8-K

What Happened
Bioxytran, Inc. announced it closed a private placement on March 18, 2026 and filed an 8-K on March 20, 2026 reporting the transaction. The company issued common stock and attached warrants to accredited investors to raise approximately $1.2 million in gross proceeds to fund working capital and general corporate purposes.

Key Details

• Shares issued: 21,071,667 shares of common stock.
• Price per share: approximately $0.055.
• Gross proceeds: approximately $1.2 million.
• Warrants issued: rights to purchase up to 19,750,001 shares at an exercise price of $0.12 per share; exercisable immediately and expire five years from issuance.
• Sale method: private placement under exemptions (Section 4(a)(2) and/or Rule 506 of Regulation D); investors represented they are accredited.

Why It Matters
This financing provides near-term cash (about $1.2M gross) to support Bioxytran’s operations and general corporate needs without registering the securities publicly. For shareholders, the issuance dilutes existing equity and the large number of warrants could lead to further dilution if exercised at $0.12. Investors should note the company’s stated use of proceeds (working capital and general corporate purposes) and monitor future disclosures for net proceeds, spending plans, and any warrant exercises.